Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elenbecestat in Early Alzheimer's Disease (24‑Month, Placebo-Controlled Phase 3 Study in Japan)
jRCT2080223508Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing Elenbecestat 50 mg QD with Placebo QD (2 arms). Started Apr 2017; status: completed.
02
Drugs
elenbecestat
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080223508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223508.